HC Wainwright & Co. Maintains Buy on Cabaletta Bio, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Cabaletta Bio (NASDAQ:CABA) and raises the price target from $17 to $25.
November 10, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cabaletta Bio's price target has been raised from $17 to $25 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Cabaletta Bio. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100